MTX-201 / Mozart Therap - LARVOL DELTA

PRECLINICAL TESTING OF A BISPECIFIC ANTIBODY TARGETING INHIBITORY KIR AND ICOS DESIGNED FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE PATIENTS (DDW 2025) - "Collectively, our preclinical data support the development of MTX-201 as a therapeutic to restore CD8 Treg functions in patients for the treatment of IBD."

IO biomarker • Preclinical • Acute Graft versus Host Disease • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CD34 • CD8 • ICOS • IL15 • KIR2DL1

PRECLINICAL TESTING OF A BISPECIFIC ANTIBODY TARGETING INHIBITORY KIR AND ICOS DESIGNED FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (CCCongress 2025) - "Collectively, our data support the development of MTX-201 as a therapeutic to restore CD8 Treg functions in patients for the treatment of IBD."

IO biomarker • Preclinical • Acute Graft versus Host Disease • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CD34 • CD8 • ICOS • IL15 • KIR2DL1

Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn’s and Colitis Congress (Businesswire) - "The presentation findings highlight that MTX-201: Selectively binds and activates CD8 Treg; does not activate cells that express only one target, including other ICOS-expressing immune cells; Extends survival and decreases disease score in a murine model of acute GvHD; Does not inhibit immune responses to common viral and microbial pathogens; Reduces gut epithelial cell death and improves epithelial cell health in organoids derived from Crohn's patients' tissues....Data demonstrate that MTX-201 binds CD8 Treg, selectively eliminates pathogenic CD4 T cells, and may decrease inflammation and reduce epithelial cell damage in IBD."

Preclinical • Acute Graft versus Host Disease • Crohn's disease • Inflammatory Bowel Disease

Mozart Therapeutics to Present Pre-clinical Data on KIR x ICOS CD8 Treg Modulator at Immunology 2024 Meeting (PRNewswire) - "Mozart Therapeutics...announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells. The data will be presented during the Immunology 2024 meeting, May 3–7 in Chicago, Illinois....Selectively activates CD8 Treg with dose-dependent increases in both their prevalence and capacity to eliminate pathogenic CD4 T cells. Enhances ICOS signaling only in CD8 Treg and not other ICOS-expressing immune cells. Reduces proinflammatory cytokines and improves survival in a highly inflammatory disease model...Our preclinical data underscore the potential of our KIR x ICOS CD8 Treg Modulator as a selective therapeutic approach for highly inflammatory autoimmune diseases, including Crohn's disease and ulcerative colitis."

Preclinical • Crohn's disease • Ulcerative Colitis

A NOVEL BISPECIFIC CD8 TREG MODULATOR TARGETING CYTOLYTIC CD8 REGULATORY T CELLS REDUCES PATHOGENIC CD4 T CELLS AND INFLAMMATION IN TRANSLATIONAL MODELS OF INTESTINAL AUTOIMMUNE AND INFLAMMATORY DISEASE (DDW 2023) - "Our results indicate that bispecific CD8 Treg modulators activate CD8 Tregs in vitro, in vivo, and in human tissue resulting in decreased inflammation and amelioration of disease. The data suggest that this network can be targeted by immune-modulating biologics to suppress pathogenic T cells, to reduce disease severity & delay onset, and to potentially mitigate severity & frequency of flares in patients with Celiac disease and IBD."

Acute Graft versus Host Disease • Celiac Disease • Crohn's disease • Gastroenterology • Graft versus Host Disease • Immune Modulation • Immunology • Inflammation • Inflammatory Bowel Disease • CD4 • CD8